How to take budesonide delayed-release capsules?

Budesonide delayed-release capsules, as a treatment for adults with primary immunoglobulinA nephropathy (IgAN) at risk of disease progression, are designed to effectively reduce the loss of kidney function. IgA nephropathy is a relatively rare kidney disease, and its pathogenesis is closely related to the deposition of IgA in the kidneys. The drug works effectively by targeting mucosal B cells, which are the primary source of galactose-deficient IgA1 antibodies that cause IgA nephropathy.

Regarding the usage and dosage of budesonide delayed-release capsules, patients must strictly follow the instructions of their attending physician. The current recommended treatment duration is 9 months, and the safety and efficacy of subsequent courses of treatment have yet to be further determined. In terms of dosage, the recommended daily dose of budesonide delayed-release capsules is 16 mg, taken orally once. It should be noted that when treatment is discontinued, the dose should be adjusted to 8 mg once daily during the last 2 weeks of treatment.

When taking budesonide delayed-release capsules, patients also need to pay attention to the time and method of taking the medicine. Extended-release capsules should be swallowed whole in the morning, at least 1 hour before meals. Patients should not try to open, squeeze or chew the capsules to avoid damaging the sustained-release structure of the drug and affecting the absorption rate and therapeutic effect.

If the patient accidentally misses a dose, he or she should continue to take the prescribed dose at the next scheduled time and should not double the dose to make up for the missed dose. Because doubling the dose may cause the drug to accumulate in the body, increasing the risk of adverse reactions.

At the same time, patients should not suddenly stop taking budesonide delayed-release capsules. If the drug needs to be discontinued, the dose should be gradually reduced under the guidance of a doctor to ensure a smooth transition of treatment and avoid possible withdrawal reactions.

In addition, a patient's dosage needs may change if he or she is undergoing surgery, is ill, or is under stress. In this case, the patient should communicate with the doctor in time and adjust the medication plan according to the specific situation. Patients should not change the dosage or medication plan without the doctor's permission, so as not to affect the treatment effect or cause unnecessary risks.

Patients who take budesonide delayed-release capsules for a long time may need regular medical examinations to monitor the therapeutic effects and possible adverse reactions of the drug. These examinations help doctors understand the patient's physical condition in a timely manner, adjust medication plans, and ensure the safety and effectiveness of treatment.

In short, budesonide delayed-release capsules are an effective treatment for adults with IgAN, but their usage and dosage must strictly follow the doctor's instructions. Patients should take the medicine on time and in the right amount, pay attention to the time and method of taking the medicine, and do not change the dosage or medication plan without authorization. At the same time, patients should undergo regular medical examinations to monitor treatment effects and adverse reactions to ensure the smooth progress of treatment.

Reference materials:https://www.drugs.com/history/tarpeyo.html